Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer

Hasan GUNDOGDU, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim Dalı, Rize, Türkiye)
Osman KUPIK (Sıtkı Koçman Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Muğla, Türkiye)
Experimental Biomedical Research
2 0
Yıl: 2021 Cilt: 4 Sayı: 3 Sayfa Aralığı: 206 - 215 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2021370075 İndeks Tarihi: 08-10-2021

Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer

Öz:
Aim: We visually and quantitatively investigated the success of using 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) and magnetic resonance imaging (MRI) [Dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI)] separately and together in detecting axillary lymph node metastasis in patients with newly diagnosed breast cancer. Methods: One hundred and thirteen patients who underwent 18F FDG PET/CT were evaluated, 102 patients of these patients had also MRI (DEC + DWI). Primary tumour size (Tsize), SUVmax of primary tumour (SUVmaxT), short diameter of largest axillary lymph node on PET/CT (LnDPET/CT), SUVmax of axillary lymph node (SUVmaxLn), metabolic tumour volume of the primary tumour (MTV), short diameter of largest axillary lymph node on MRI (LnDMRI), the presence of fatty hilum absence and apparent diffusion coefficient (ADC) were evaluated. Results: In visual analysis, sensitivity and specificity values of 18F FDG PET/CT, MRI and MRI+18F FDG PET/CT were 78.85, 94% – 72.27%, 96.15 – 83.87%, 98.04%, respectively. In the quantitative evaluation, ADC≤1.2 x 10-3 mm2/sec (OR = 6.665, p = 0.001, 95CI%: 2.181–20.370) and LnSUVmax> 2 (OR = 15.2, p<0.001, 95CI%: 4.587–50.376) were independent predictors in detecting axillary lymph node metastasis. Conclusion: LnSUVmax >2 and ADC ≤ 1.2 x 10-3 mm2/sec can be used as independent predictors of detecting axillary lymph node metastasis in patients with newly diagnosed breast cancer.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1]Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(19:181-87.
  • [2]Crane-Okada R, Wascher RA, Elashoff D, et al. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008; 15(7):1996-2005.
  • [3]Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005; 23(19):4312-21.
  • [4]Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53.
  • [5]Monzawa S, Adachi S, Suzuki K, et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl Med. 2009; 23(10):855-61.
  • [6]McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000; 18(13):2560-66.
  • [7]Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymphnode dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8810):881-88.
  • [8]Wilke LG, McCall LM, Posther KE et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006; 13(4):491-500.
  • [9]Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009; 36(10):1543-50.
  • [10]Kvistad K, Rydland J, Smethurst H-B, et al. Axillary lymph node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol. 2000; 10(9):1464-71.
  • [11]Ahn J-H, Son EJ, Kim J-A, et al. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer. Acta Radiol. 2010; 51(8):859-65.
  • [12]Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2010; 123(1):281-90.
  • [13]Zhang Y, Qin Q, Li B, et al. Magnetic resonance imaging for N staging in non‐ small cell lung cancer: A systematic review and meta‐analysis. Thorac Cancer. 2015; 6(2):123-32.
  • [14]Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. Eur Radiol. 2012; 22(1):26-38.
  • [15]Kim EJ, Kim SH, Kang BJ, et al. Diagnostic value of breast MRI for predicting metastatic axillary lymph nodes in breast cancer patients: diffusion-weighted MRI and conventional MRI. J Magn Reson Imaging. 2014; 32(10):1230-36.
  • [16]Fornasa F, Nesoti MV, Bovo C, et al. Diffusion‐weighted magnetic resonance imaging in the characterization of axillary lymph nodes in patients with breast cancer. J Magn Reson Imaging. 2012; 36(4):858-64.
  • [17]Kamitani T, Hatakenaka M, Yabuuchi H, et al. Detection of axillary node metastasis using diffusion-weighted MRI in breast cancer. Clin. Imaging. 2013; 37(1):56-61.
  • [18]Liang X, Yu J, Wen B, et al. MRI and FDGPET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. Clin Radiol. 2017; 72(4):295- 301.
  • [19]An Y-S, Lee D, Yoon J-K, et al. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Nuklearmedizin. 2014; 53(3):89-94.
  • [20]An Y-S, Kang DK, Jung Y, et al. Volumebased metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis. Medicine. 2017; 96(45):e8557.
  • [21]Yoo J, Kim BS, Yoon H-J. Predictive value of primary tumor parameters using 18 FFDG PET/CT for occult lymph node metastasis in breast cancer with clinically negative axillary lymph node. Ann Nucl Med. 2018; 32(9):642-48.
  • [22]Kim JY, Lee SH, Kim S, et al. Tumour 18 FFDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2- positive breast cancer subtypes. Eur Radiol. 2015 ;25(4):1172-81.
  • [23]Sun WY, Choi YJ, Song Y-J. Prediction of Axillary Nodal Status according to the Axillary Lymph Node to Primary Breast Tumor Maximum Standardized Uptake Value Ratio on 18 F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. J Breast Dis. 2016; 4(2):92- 99.
  • [24]Chung J, Youk JH, Kim J-A, et al. Role of diffusion-weighted MRI: predicting axillary lymph node metastases in breast cancer. Acta Radiol. 2014; 55(8):909-16.
  • [25]Rautiainen S, Könönen M, Sironen R, et al. Preoperative axillary staging with 3.0-T breast MRI: clinical value of diffusion imaging and apparent diffusion coefficient. PLoS One. 2015; 10:e0122516.
  • [26]Mortellaro VE, Marshall J, Singer L, et al. Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging. 2009; 30(2):309-12.
APA GÜNDOĞDU H, kupik o (2021). Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. , 206 - 215. 10.30714/j-ebr.2021370075
Chicago GÜNDOĞDU HASAN,kupik osman Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. (2021): 206 - 215. 10.30714/j-ebr.2021370075
MLA GÜNDOĞDU HASAN,kupik osman Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. , 2021, ss.206 - 215. 10.30714/j-ebr.2021370075
AMA GÜNDOĞDU H,kupik o Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. . 2021; 206 - 215. 10.30714/j-ebr.2021370075
Vancouver GÜNDOĞDU H,kupik o Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. . 2021; 206 - 215. 10.30714/j-ebr.2021370075
IEEE GÜNDOĞDU H,kupik o "Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer." , ss.206 - 215, 2021. 10.30714/j-ebr.2021370075
ISNAD GÜNDOĞDU, HASAN - kupik, osman. "Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer". (2021), 206-215. https://doi.org/10.30714/j-ebr.2021370075
APA GÜNDOĞDU H, kupik o (2021). Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. Experimental Biomedical Research, 4(3), 206 - 215. 10.30714/j-ebr.2021370075
Chicago GÜNDOĞDU HASAN,kupik osman Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. Experimental Biomedical Research 4, no.3 (2021): 206 - 215. 10.30714/j-ebr.2021370075
MLA GÜNDOĞDU HASAN,kupik osman Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. Experimental Biomedical Research, vol.4, no.3, 2021, ss.206 - 215. 10.30714/j-ebr.2021370075
AMA GÜNDOĞDU H,kupik o Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. Experimental Biomedical Research. 2021; 4(3): 206 - 215. 10.30714/j-ebr.2021370075
Vancouver GÜNDOĞDU H,kupik o Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer. Experimental Biomedical Research. 2021; 4(3): 206 - 215. 10.30714/j-ebr.2021370075
IEEE GÜNDOĞDU H,kupik o "Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer." Experimental Biomedical Research, 4, ss.206 - 215, 2021. 10.30714/j-ebr.2021370075
ISNAD GÜNDOĞDU, HASAN - kupik, osman. "Comparison of 18F FDG PET / CT, MRI (DWI + DCE) and MRI + 18F FDG PET/CT in thedetection of axillary metastatic lymph nodes in patients with newly diagnosed breast cancer". Experimental Biomedical Research 4/3 (2021), 206-215. https://doi.org/10.30714/j-ebr.2021370075
Sayfa Oluşturulma Tarihi
17-04-2024 21:32

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları